Auditing a breast MRI practice: performance measures for screening and diagnostic breast MRI.
OBJECTIVE
Breast MRI is increasingly used for both screening and diagnostic purposes. Although performance benchmarks for screening and diagnostic mammography have been published, performance benchmarks for breast MRI have yet to be established. The purpose of this study was to comprehensively evaluate breast MRI performance measures, stratified by screening and diagnostic indications, from a single academic institution.


METHODS
Institutional review board approval was acquired for this HIPAA-compliant study. Informed consent was not required. Retrospective review of the institutional database identified all breast MRI examinations performed from April 1, 2007, to March 31, 2008. After application of exclusion criteria, the following performance measures for screening and diagnostic indications were calculated: cancer detection rate, positive predictive value (PPV), and abnormal interpretation rates.


RESULTS
The study included 2,444 examinations, 1,313 for screening and 1,131 for diagnostic indications. The cancer detection rates were 14 per 1,000 screening breast MRI examinations and 47 per 1,000 diagnostic examinations (P < .00001). The abnormal interpretation rate was 12% (152 of 1,313) for screening and 17% (194 of 1,131) for diagnostic indications (P = .00008). The PPVs of MRI were lower for screening [PPV1 (abnormal findings) = 12%, PPV2 (biopsy recommended) = 24%, PPV3 (biopsy performed) = 27%] compared with diagnostic indications (PPV1 (abnormal findings) = 28%, PPV2 (biopsy recommended) = 36%, PPV3 (biopsy performed) = 38%].


CONCLUSIONS
Breast MRI performance measures differ significantly between screening and diagnostic MRI indications. Medical audits for breast MRI should calculate performance measures for screening and diagnostic breast MRI separately, as recommended for mammography.
Avon Comprehensive Breast Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: bniell@partners.org.
Bethany L
BL
Niell
Department of Radiology, Christiana Care Health System, Newark, Delaware.
Sara C
SC
Gavenonis
University of Texas Health Science Center, San Antonio School of Medicine, San Antonio, Texas.
Tina
T
Motazedi
Department of Radiology, Massachusetts General Hospital, Institute for Technology Assessment, Boston, Massachusetts.
Jessica Cott
JC
Chubiz
Department of Radiology, Massachusetts General Hospital, Institute for Technology Assessment, Boston, Massachusetts.
Elkan P
EP
Halpern
Avon Comprehensive Breast Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts.
Elizabeth A
EA
Rafferty
Department of Radiology, Massachusetts General Hospital, Institute for Technology Assessment, Boston, Massachusetts.
Janie M
JM
Lee
D001706:Biopsy; D001943:Breast Neoplasms / Q000175:diagnosis*; D003287:Contrast Media; D005260:Female; D019786:Gadolinium DTPA; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000592:standards*; D008403:Mass Screening; D008485:Medical Audit; D008875:Middle Aged; D011237:Predictive Value of Tests; D012189:Retrospective Studies
D003287:Contrast Media; D019786:Gadolinium DTPA
Audit; abnormal interpretation rate; breast MRI; cancer detection rate; positive predictive value